HotSpot Therapeutics Appoints Niti Goel, M.D., as Chief Medical Officer

HST-2011Positive

AI Analysis

Summary

HotSpot Therapeutics appointed Niti Goel, M.D., as Chief Medical Officer to lead clinical development of HST-2011, a small molecule IRF5 inhibitor nominated as a development candidate for lupus and other autoimmune diseases.

Importance:3/10

Sentiment:

0.30

ManagementClinical DevelopmentIRF5 InhibitorAutoimmuneLupus

Related Companies

$INTI $MDCE

Read the original article

Published by PR Newswire Clinical Trials on August 18, 2026 11:00 AM

Read Original